Article

Failures in diagnosis and monitoring plague management of bacterial keratitis

Establishing the correct diagnosis and modifying therapy appropriately based on response are fundamental in the successful management of bacterial keratitis, said Richard L. Abbott, MD, at the World Congress of Ophthalmology.

Establishing the correct diagnosis and modifying therapy appropriately based on response are fundamental in the successful management of bacterial keratitis, said Richard L. Abbott, MD, at the World Congress of Ophthalmology.

"Left untreated, microbial keratitis leads to progressive tissue destruction with potential corneal perforation and extension to adjacent structures. Determining etiology is critical for effective management," said Dr. Abbott, the Thomas W. Boyden Professor of Ophthalmology, Beckman Vision Center, University of California at San Francisco.

In their clinical evaluation, ophthalmologists need to recognize there are many conditions that are masqueraders of bacterial keratitis. Therefore, obtaining a culture with use of proper sampling and plating technique is critical in all suspect cases.

Once treatment is initiated, patients need to be closely observed to determine if the infection is responding, worsening, or if the changing clinical picture is indicative of medication-related toxicity. Dr. Abbott recommended creating a carefully drawn diagram in the chart that includes information about: 1) the depth and density of the infiltration, 2) thinning, 3) the presence and density of white blood cells around the infiltrate, and 4) the size and density of hypopyon. Those features should then be followed in the evaluation of the treatment response.

In the current era, treatment is usually initiated with a fourth-generation fluoroquinolone administered in an intensive regimen for the first several days. Once there is evidence of therapeutic response, the treatment should be tapered to avoid toxicity, but fluoroquinolone administration frequency should never be reduced to below four times a day. When fluoroquinolone discontinuation is deemed appropriate, clinicians who wish to maintain antibiotic coverage may prescribe bacitracin, as that agent offers broad-spectrum activity and is well-tolerated, said Dr. Abbott.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.